New treatment for opioid addiction using a brain-targeting drug
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders
['FUNDING_OTHER'] · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · NIH-10925412
This study is testing a new drug called SBI-553 that aims to help people with opioid use disorder by working on a specific brain receptor to improve treatment without the harsh side effects of current options.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10925412 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel drug, SBI-553, that targets the neurotensin 1 receptor (NTR1) in the brain to help treat opioid use disorder (OUD). The approach involves creating a compound that can effectively modulate the brain's dopamine system without the severe side effects associated with existing treatments. By using advanced techniques to ensure the drug can penetrate the brain, the researchers aim to provide a safer and more effective option for individuals struggling with addiction. The study includes both laboratory and animal testing to evaluate the drug's efficacy and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking new treatment options.
Not a fit: Patients who are not struggling with opioid addiction or those who have not responded to other treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, safer treatment option for individuals suffering from opioid addiction.
How similar studies have performed: While there have been studies on NTR1 as a target for addiction treatment, the specific approach using SBI-553 is novel and has not been previously documented.
Where this research is happening
LA JOLLA, UNITED STATES
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JACKSON, MICHAEL — SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- Study coordinator: JACKSON, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.